Pacira Pharmaceuticals (NASDAQ:PCRX) received a $54.00 price target from research analysts at Royal Bank of Canada in a research report issued on Thursday, January 4th. The brokerage currently has a “buy” rating on the stock. Royal Bank of Canada’s price objective points to a potential upside of 44.97% from the company’s current price.

A number of other equities research analysts have also commented on the company. CIBC assumed coverage on Pacira Pharmaceuticals in a research report on Thursday, September 7th. They issued a “market perform” rating for the company. UBS Group assumed coverage on Pacira Pharmaceuticals in a research report on Wednesday, September 6th. They set a “market perform” rating for the company. Zacks Investment Research lowered Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. Bank of America decreased their target price on Pacira Pharmaceuticals from $46.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, October 4th. Finally, Janney Montgomery Scott downgraded Pacira Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $27.00 price target for the company. in a research note on Thursday, October 26th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. Pacira Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $49.06.

Shares of Pacira Pharmaceuticals (PCRX) traded down $0.80 during trading hours on Thursday, hitting $37.25. The stock had a trading volume of 98,449 shares, compared to its average volume of 804,997. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a one year low of $29.81 and a one year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. The company had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. Pacira Pharmaceuticals’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.20 earnings per share. equities analysts predict that Pacira Pharmaceuticals will post -0.85 EPS for the current fiscal year.

In related news, CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total transaction of $2,257,650.90. Following the transaction, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at approximately $6,102,347.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark A. Kronenfeld acquired 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average cost of $41.60 per share, for a total transaction of $41,600.00. Following the completion of the acquisition, the director now owns 6,795 shares in the company, valued at approximately $282,672. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 98,960 shares of company stock valued at $3,868,341. Corporate insiders own 6.60% of the company’s stock.

A number of institutional investors have recently made changes to their positions in PCRX. HealthCor Management L.P. increased its stake in Pacira Pharmaceuticals by 63.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after purchasing an additional 693,799 shares during the period. Eaton Vance Management purchased a new position in Pacira Pharmaceuticals in the 2nd quarter worth approximately $19,519,000. Mesirow Financial Investment Management Equity Management purchased a new position in Pacira Pharmaceuticals in the 3rd quarter worth approximately $14,671,000. Stonepine Capital Management LLC purchased a new position in Pacira Pharmaceuticals in the 3rd quarter worth approximately $14,089,000. Finally, Epoch Investment Partners Inc. increased its stake in Pacira Pharmaceuticals by 195.7% in the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after purchasing an additional 354,728 shares during the period.

WARNING: “Royal Bank of Canada Analysts Give Pacira Pharmaceuticals (NASDAQ:PCRX) a $54.00 Price Target” was published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.mareainformativa.com/royal-bank-of-canada-reiterates-54-00-price-target-for-pacira-pharmaceuticals-pcrx-updated-updated-updated/126737/.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.